NYSE$MTNB
Matinas BioPharma Holdings Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Matinas BioPharma reported financial results for the first quarter ended March 31, 2020, and provided a corporate update and outlook for 2020.
Matinas BioPharma reported a net loss attributable to common shareholders of $5.2 million, or a net loss per share of $0.03 for the first quarter of 2020. The company's cash, cash equivalents, and marketable securities were approximately $71.2 million as of March 31, 2020, sufficient to fund operations into the first half of 2023.
- ENHANCE-IT study of MAT9001 against Vascepa® is set to resume in June 2020.
- EnACT study of MAT2203 in cryptococcal meningitis is expected to resume in June 2020.
- The COVID-19 pandemic has not had a material impact on the business.
- Cash resources are sufficient to fund operations into the first half of 2023.
Headline financials
Revenue & EPS history
Matinas BioPharma · Revenue · Quarterly
$0
Forward guidance
Matinas BioPharma believes that cash on hand is sufficient to fund operations into the first half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-2.1%
Avg return
Earnings day
-2.9%
Avg return
5 days after
-1.9%
Avg return
30 days after
37%
14 / 38 earnings
Positive
+43.0%
Q2 2025
Best reaction
-41.3%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +2.6% | +4.3% | -32.2% | |
| Q2 2025 | +43.0% | +5.5% | +10.9% | |
| Q2 2024 | -1.3% | +9.0% | +17.3% | |
| Q1 2025 | +6.3% | +2.5% | +15.0% | |
| Q4 2025 | -6.0% | -7.5% | +21.2% | |
| Q3 2024 | -15.0% | -18.1% | -23.9% | |
| Q1 2024 | -1.1% | -1.1% | -10.7% | |
| Q4 2023 | -5.2% | +29.4% | -37.4% | |
| Q3 2023 | -24.3% | -31.9% | -21.9% | |
| Q2 2023 | -41.3% | -50.0% | -50.9% | |
| Q1 2023 | -12.5% | -15.5% | -26.0% | |
| Q4 2022 | +2.1% | -11.1% | -2.2% | |
| Q3 2022 | -3.3% | -5.0% | -15.2% | |
| Q2 2022 | -4.7% | -8.4% | -12.9% | |
| Q1 2022 | +6.7% | +6.5% | +32.0% | |
| Q4 2021 | +12.9% | +6.9% | +40.0% | |
| Q3 2021 | -6.8% | -2.8% | +3.7% | |
| Q2 2021 | -2.5% | -5.7% | +2.7% | |
| Q1 2021 | +2.6% | -3.8% | +7.1% | |
| Q4 2020 | -2.7% | -1.8% | -98.3% | |
| Q3 2020 | -2.6% | -3.6% | +29.0% | |
| Q2 2020 | -3.8% | -7.2% | -22.0% | |
| Q1 2020 | +8.9% | +11.7% | +29.7% | |
| Q4 2019 | -14.6% | -34.0% | -49.1% | |
| Q3 2019 | -4.8% | +31.2% | +96.8% | |
| Q2 2019 | +6.2% | +6.7% | +2.1% | |
| Q1 2019 | +1.8% | +10.0% | -7.8% | |
| Q4 2018 | -0.9% | -1.8% | -7.2% | |
| Q3 2018 | -25.2% | -29.8% | -28.8% | |
| Q2 2018 | -1.4% | +5.0% | +26.1% | |
| Q1 2018 | -1.0% | +0.6% | +8.6% | |
| Q4 2017 | -5.5% | -12.8% | -38.8% | |
| Q3 2017 | +2.6% | +4.4% | +24.6% | |
| Q2 2017 | +14.4% | +5.6% | +9.6% | |
| Q1 2017 | +2.9% | +7.6% | -7.3% | |
| Q3 2016 | -6.3% | -4.0% | -20.0% | |
| Q2 2016 | +3.2% | +1.5% | +64.7% | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro